AIM: To extend to biomarker studies the consensus clinical significance criterion of a three-point difference in Hamilton Rating Scale for Depression. MATERIALS & METHODS: We simulated datasets modeled on large clinical trials. RESULTS: In a typical clinical trial comparing active treatment and placebo, a difference of three Hamilton Rating Scale for Depression (HRSD) points at the end of treatment corresponds to 6.3% of variance in outcome explained. To achieve a similar explanatory power, genotypes with minor allele frequencies of 5, 10, 20, 30 and 50% need to attain a per allele difference of 4.7, 3.6, 2.8, 2.4 and 2.2 HRSD points, respectively. A normally distributed continuous biomarker will need an effect size of 1.5 HRSD points per standard deviation. A number needed to assess of three suggests that with this effect size, a biomarker will significantly improve the prediction of outcome in one out of every three patients assessed. CONCLUSION: This report provides guidance on assessing clinical significance of biomarkers predictive of outcome in depression treatment.
AIM: To extend to biomarker studies the consensus clinical significance criterion of a three-point difference in Hamilton Rating Scale for Depression. MATERIALS & METHODS: We simulated datasets modeled on large clinical trials. RESULTS: In a typical clinical trial comparing active treatment and placebo, a difference of three Hamilton Rating Scale for Depression (HRSD) points at the end of treatment corresponds to 6.3% of variance in outcome explained. To achieve a similar explanatory power, genotypes with minor allele frequencies of 5, 10, 20, 30 and 50% need to attain a per allele difference of 4.7, 3.6, 2.8, 2.4 and 2.2 HRSD points, respectively. A normally distributed continuous biomarker will need an effect size of 1.5 HRSD points per standard deviation. A number needed to assess of three suggests that with this effect size, a biomarker will significantly improve the prediction of outcome in one out of every three patients assessed. CONCLUSION: This report provides guidance on assessing clinical significance of biomarkers predictive of outcome in depression treatment.
Authors: R Uher; R H Perlis; N Henigsberg; A Zobel; M Rietschel; O Mors; J Hauser; M Z Dernovsek; D Souery; M Bajs; W Maier; K J Aitchison; A Farmer; P McGuffin Journal: Psychol Med Date: 2011-09-20 Impact factor: 7.723
Authors: Thomas J Carmody; A John Rush; Ira Bernstein; Diane Warden; Stephen Brannan; Daniel Burnham; Ada Woo; Madhukar H Trivedi Journal: Eur Neuropsychopharmacol Date: 2006-06-12 Impact factor: 4.600
Authors: A John Rush; Maurizio Fava; Stephen R Wisniewski; Philip W Lavori; Madhukar H Trivedi; Harold A Sackeim; Michael E Thase; Andrew A Nierenberg; Frederic M Quitkin; T Michael Kashner; David J Kupfer; Jerrold F Rosenbaum; Jonathan Alpert; Jonathan W Stewart; Patrick J McGrath; Melanie M Biggs; Kathy Shores-Wilson; Barry D Lebowitz; Louise Ritz; George Niederehe Journal: Control Clin Trials Date: 2004-02
Authors: Christian A Webb; Zachary D Cohen; Courtney Beard; Marie Forgeard; Andrew D Peckham; Thröstur Björgvinsson Journal: J Consult Clin Psychol Date: 2020-01
Authors: C Fabbri; K E Tansey; R H Perlis; J Hauser; N Henigsberg; W Maier; O Mors; A Placentino; M Rietschel; D Souery; G Breen; C Curtis; L Sang-Hyuk; S Newhouse; H Patel; M Guipponi; N Perroud; G Bondolfi; M O'Donovan; G Lewis; J M Biernacka; R M Weinshilboum; A Farmer; K J Aitchison; I Craig; P McGuffin; R Uher; C M Lewis Journal: Pharmacogenomics J Date: 2017-11-21 Impact factor: 3.550
Authors: Murray B Stein; Aparna Keshaviah; Stephen A Haddad; Michael Van Ameringen; Naomi M Simon; Mark H Pollack; Jordan W Smoller Journal: Neuropsychopharmacology Date: 2013-10-24 Impact factor: 7.853
Authors: Karim Malki; Maria Grazia Tosto; Héctor Mouriño-Talín; Sabela Rodríguez-Lorenzo; Oliver Pain; Irfan Jumhaboy; Tina Liu; Panos Parpas; Stuart Newman; Artem Malykh; Lucia Carboni; Rudolf Uher; Peter McGuffin; Leonard C Schalkwyk; Kevin Bryson; Mark Herbster Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2016-10-01 Impact factor: 3.568
Authors: Christian A Webb; Madhukar H Trivedi; Zachary D Cohen; Daniel G Dillon; Jay C Fournier; Franziska Goer; Maurizio Fava; Patrick J McGrath; Myrna Weissman; Ramin Parsey; Phil Adams; Joseph M Trombello; Crystal Cooper; Patricia Deldin; Maria A Oquendo; Melvin G McInnis; Quentin Huys; Gerard Bruder; Benji T Kurian; Manish Jha; Robert J DeRubeis; Diego A Pizzagalli Journal: Psychol Med Date: 2018-07-02 Impact factor: 7.723
Authors: Annamaria Cattaneo; Massimo Gennarelli; Rudolf Uher; Gerome Breen; Anne Farmer; Katherine J Aitchison; Ian W Craig; Christoph Anacker; Patricia A Zunsztain; Peter McGuffin; Carmine M Pariante Journal: Neuropsychopharmacology Date: 2012-09-19 Impact factor: 7.853